Citi says Alnylam (ALNY) reported “highly impressive” Phase 3 HELIOS-B Amvuttra data in ATTR amyloidosis with cardiomyopathy. Sanofi (SNY) receives tiered 15%-30% royalties on global Amvuttra sales, the analyst tells investors in a research note. The firm expects a positive share price reaction, reflecting the “underappreciated multi-billion dollar royalty stream.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi, Biovac spearhead polio vaccine manufacturing capabilities in Africa
- Innate Pharma announces updated results from SAR443579/IPH6101
- Novavax price target raised to $18 from $12 at BofA
- Sanofi’s Dupixent Awaits Extended FDA Review
- Regeneron, Sanofi announce FDA approved Kevzara for treatment of pJIA